EPA 749-F-94-004a     http://www.epa.gov/chemfact/s_acenit.txt

         CHEMICAL SUMMARY FOR ACETONITRILE (CAS NO. 75-05-8)
                             prepared by
              OFFICE OF POLLUTION PREVENTION AND TOXICS
                U.S. ENVIRONMENTAL PROTECTION AGENCY
                             August 1994

   This summary is based on information retrieved from a systematic
search limited to secondary sources (see Appendix A).  These sources
include online databases, unpublished EPA information, government
publications, review documents, and standard reference materials.  No
attempt has been made to verify information in these databases and
secondary sources.

Acetonitrile is metabolized in the body to hydrogen cyanide and    thiocyanate; these chemicals are thought to be
responsible for the  adverse effects of acetonitrile.


II. PRODUCTION, USE, AND TRENDS

   A. Production

      There are four producers of acetonitrile in the United States:
      BP Chemicals; Dupont; J.T. Baker Chemical; and Sterling Chemicals.
      In 1992, 14.7 million kilograms (32.3 million pounds) were
      produced in the United States. (U.S. International Trade
      Commission 1994).

   B. Use

      Acetonitrile has a number of uses, primarily as an extraction
      solvent for butadiene; as a chemical intermediate in pesticide
      manufacturing; and as a solvent for both inorganic and organic
      compounds.  Uses also include use as a starting material for the
      production of acetophenone, alpha-naphthalenacetic acid, thiamine,
      and acetamidine; to remove tars, phenols, and coloring matter
      from petroleum hydrocarbons not soluble in acetonitrile; in the
      production of acrylic fibers; and in pharmaceuticals, perfumes,
      nitrile rubber, and ABS (acrylonitrile-butadiene-styrene) resins
      (HSDB 1994).

   C. Trends

      Because it is a byproduct of acrylonitrile production, production
      trends for acetonitrile should follow trends in acrylonitrile
      production, which are expected to generally mirror trends in
      United States economic growth (Mannsville, "Acrylonitrile," 1992.)

III. ENVIRONMENTAL FATE

   A. Environmental Release

      Of the total acetonitrile released to the environment in 1992,
      11.3 million pounds were into the atmosphere, 20 million pounds
      were into underground sites, 50 thousand pounds were into surface
      water, and only 29 pounds were onto the land (TRI92 1994).  
      Acetonitrile has been detected in air near ground levels, ranging
      from 2 to 7 ppb in both urban and rural areas (HSDB 1994).  The
      chemical occurs naturally in coal tar and cigarette smoke (HSDB
      1994).

   B. Transport

      Acetonitrile is expected to adsorb weakly to soils as predicted
      by its KOC value; removal occurs primarily by volatilization and
      leaching into groundwater (HSDB 1994).  Volatilization from
      surface waters is slow due to the high water solubility, moderate
      vapor pressure (91.1 mm Hg), and low Henry's law constant (3.46 x
      10-5 atmùm3/mole) of the chemical (HSDB 1994).  The water
      solubility of acetonitrile suggests that dissolution into clouds
      and raindrops may occur leading to possible removal in rainfall
      (U.S. EPA 1985).




IV. HUMAN HEALTH EFFECTS

  Acetonitrile is metabolized in the body to hydrogen cyanide and
  thiocyanate; these chemicals are thought to be responsible for the
  adverse effects of acetonitrile.

  A. Pharmacokinetics

     1. Absorption - Absorption of acetonitrile occurs after oral,
        dermal, or inhalation exposure.  Although no quantitative
        absorption data were found for oral exposure, signs of acute
        toxicity, observed after oral exposure, indicate that absorption
        occurs (U.S. EPA 1987).  In humans, 74% of acetonitrile was
        absorbed from cigarette smoke held in the mouth for 2 seconds;
        when inhaled into the lungs, absorption increased to 91% (U.S.
        EPA 1985; 1987).  Dogs exposed by inhalation to 16,000 ppm for
        4 hours appeared to reach steady-state blood concentrations
        within 3-4 hours (U.S. EPA 1985; 1987).

    2. Distribution - Acetonitrile and its metabolites are transported
       throughout the body in the blood (U.S. EPA 1985).  After oral or
       inhalation exposures to experimental animals, parent compound or
       metabolites were found in the brain, heart, liver, kidney,
       spleen, blood, stomach, and muscle (U.S. EPA 1985).  After a fatal
       human inhalation exposure, metabolites were also found in those
       organs as well as skin, lungs, intestine, testes, and urine (U.S.
       EPA 1985).

    3. Metabolism - Acetonitrile is metabolized to hydrogen cyanide
       and thiocyanate which are responsible for the toxic effects
       of the chemical (HSDB 1994; U.S. EPA 1985).  Metabolism is
       mediated by the cytochrome P-450 system (U.S. EPA 1985).

    4. Excretion - Acetonitrile is excreted as the parent chemical in
       expired air and as parent or metabolite in urine (U.S. EPA 1985).
       Urinary excretion of thiocyanate following oral exposure in rats
       ranged from 11.8% (U.S. EPA 1985) to 37% (HSDB 1994) of
       administered dose.  Concentrations of acetonitrile of 2.2-20
       microgram/100 mL of urine have been found for heavy smokers
       (U.S. EPA 1985).

  B. Acute Toxicity

     Acetonitrile liquid or vapor is irritating to the skin, eyes, and
     respiratory tract.  At high enough doses, death can occur quickly
     from respiratory failure.  Lower doses cause typical symptoms of
     cyanide poisoning such as salivation, nausea, vomiting, anxiety,
     confusion, hyperpnea, dyspnea, rapid pulse, unconsciousness, and
     convulsions.  

     1. Humans - Liquid or vapor acetonitrile is irritating to eyes,
        skin, nose, and throat (Keith and Walters 1985). Concentrations
        of acetonitrile vapor up to 500 ppm cause irritation of mucous
        membranes (HSDB 1994).  Volunteers were exposed to 40, 80, or
        160 ppm for 4 hours; several hours after exposure one person had
        tightness of the chest after exposure to 40 ppm and another
        experienced flushing of the face and bronchial tightness after
        exposure to 160 ppm (ACGIH 1991).  The concentration of 160 ppm
        is roughly equivalent to a total of 19.5 mg/kg over the 4 hour
        period (see end note 1).  One photographic laboratory worker
        died after "massive" exposure to acetonitrile vapor; gastric
        distress and nausea began about 4 hours after exposure followed
        by hypersalivation, conjunctivitis, low urine output, low blood
        pressure, albumin in urine and cerebrospinal fluid, coma, and
        death due to cardiac and respiratory failure (HSDB 1994).  
        Similar signs and symptoms, including death, occurred in a worker

        painting the interior of a tank with a resin containing 30-40%
        acetonitrile (HSDB 1994).

     2. Animals - Oral LD50 values for acetonitrile in the rat range
        from 2.46 to 6.5 g/kg (U.S. EPA 1985).  The 4-hour inhalation
        LC50 varies with species from 2828 ppm in the rabbit to 16,000
        ppm in the rat; dermal LD50 values of 3.9 and 1.25 g/kg have been
        reported for the rabbit (U.S. EPA 1985).  Deaths occurred in dogs
        exposed by inhalation to 16,000 or 32,000 ppm; necropsy indicated
        pulmonary hemorrhage and vascular congestion (ACGIH 1991).

 C. Subchronic/Chronic Toxicity

    Limited information was found on the adverse effects of long term
    human exposure to acetonitrile.  Animals exposed chronically by
    inhalation have liver vacuolization, cerebral hemorrhage, lung
    lesions including focal emphysema and proliferation of alveolar
    septa, and decreases in hematological parameters.  EPA has derived an
    oral reference dose (RfD) (see end note 2) of 0.006 mg/kg/day for
    acetonitrile, based on adverse blood effects observed in animal
    inhalation studies.  Confidence in this RfD is low; it may be changed
    in the near future, pending results of further review now being
    conducted by EPA.

    1. Humans - No information was found on the adverse effects of
       long term human exposure to acetonitrile.  Brief references
       appear in HSDB (1994), suggesting that chronic exposure to
       acetonitrile may cause headache, anorexia, dizziness, weakness,
       and macular, papular, or vesicular dermatitis.  No additional
       information was provided in support of these statements.

    2. Animals - Female mice exposed to 100, 200, or 400 ppm, 6
       hours/day, 5 days/week for 90 days had thymic atrophy at the
       middle and high doses and hepatic vacuolization at the high dose;
       dose-related decreases were observed in hematocrit, blood
       hemoglobin concentration, and erythrocyte and leucocyte counts
       (U.S. EPA 1994).  A no-observed-adverse effect level (NOAEL) for
       this study was 100 ppm (equivalent to 19.3 mg/kg/day).  Based on
       these inhalation data the U.S. EPA (1994) calculated an oral
       reference dose for acetonitrile of 0.006 mg/kg/day.  Similar
       hepatic and blood profile changes were observed in mice exposed to
       200 or 400 ppm 6.5 hours/day, 5 days/week for 13 weeks (ACGIH
       1991).

       Rats exposed by inhalation to 166, 330, or 655 ppm acetonitrile
       7 hours/day, 5 days/week for 90 days had a dose-responsive
       increase in the severity of lung lesions.  Animals in the low and
       middle dose groups had "histiocytic clumps in alveoli,
       atelectasis, bronchitis or pneumonia"; high dose animals had
       alveolar congestion and focal edema, bronchial inflammation,
       desquamation, and excess mucus as well as swelling of the liver
       and kidneys and cerebral hemorrhage (U.S. EPA 1985; 1987).  Dogs
       and monkeys exposed to 350 ppm, 7 hours/day, 5 days/week for 91
       days had pulmonary lesions including focal emphysema, atelectasis
       and proliferation of alveolar septa; transient depression in
       hematocrit and hemoglobin values also occurred in dogs, and brain
       hemorrhages were observed in monkeys (U.S. EPA 1985; 1987).  
       Male and female mice (groups of 10/sex) were exposed to 25, 50,
       100, 200, or 400 ppm, 6 hours/day for 65 days. Decreased BUN, red
       blood cell counts, and hematocrit occurred in females exposed to
       the two highest doses, and increased liver weights were observed
       in males at 400 ppm and females at 100 and 200 ppm (U.S. EPA
       1987).


G. Neurotoxicity

    Exposure to high concentrations of acetonitrile causes death by
    respiratory failure and has been shown to cause brain lesions in
    animals.
   
    1. Humans - The nervous system is a major target for acetonitrile
       acute toxicity.  Acute exposure may cause salivation, nausea,
       vomiting, anxiety, confusion, hyperpnea, dyspnea, rapid pulse,
       unconsciousness, and convulsions followed by death from
       respiratory failure.  Chronic exposure may cause headache,
       anorexia, dizziness, and weakness (HSDB 1994).

    2. Animals - Acetonitrile inhalation caused cerebral hemorrhages in
       rats exposed to 655 ppm 7 hours/day, 5 days/week, for 90 days and
       monkeys exposed to 350 ppm 7 hours/day, 5 days/week, for 91 days
       (U.S. EPA 1987).